Esteve Pharmaceuticals SA (Esteve) is a specialty pharmaceutical company that is involved in the research, development, manufacture, and commercialization of novel pharmaceuticals, OTC and chemicals addressing various clinical indications. The company offers an array of products in analgesia, central nervous system (CNS), respiratory, pain, oncology, and ophthalmology.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Esteve’s research and development (R&D) activities focus on the development of novel therapeutic solutions targeting unmet medical needs. It works in areas such as in silico drug design, cellular and molecular biology, medical chemistry, pharmacology, pre-clinical development, clinical development, pharmaceutical development, quality assurance, regulatory affairs, industrial property, pharmacological safety and pharmacovigilance. Its program E-58425 has been submitted for market approval for the treatment of neuropathic pain and severe and chronic pain (moderate to intense). It has other products such as EGT-101 for gene therapy; E-64401, E-64514, E-64454 for Sigma-1 platform; and E-85819, E-86657 for Multimodal NMEs, are in preclinical development stage. The company’s R&D portfolio includes new chemical entities in fields like neurology and analgesia, and advanced therapies for inherited metabolic disorders. The company is implementing various programs that are in different stages of research and development. Esteve Pharmaceuticals SA is focusing on proprietary specialty therapies, to deliver new solutions for patients who lack effective options.